IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome

European Journal of Immunology

Volumn 45, Issue 10, 2015, Pages 2847-2857

  Rabeony, Hanitriniaina ^a   Pohin, Mathilde ^a   Vasseur, Philippe ^a,b   Petit Paris, Isabelle ^a,b   Jégou, Jean François ^a   Favot, Laure ^a   Frouin, Eric ^a,b   Boutet, Marie Astrid ^c   Blanchard, Frédéric ^c   Togbe, Dieudonnée ^d   Ryffel, Bernhard ^e   Bernard, François Xavier ^a,f   Lecron, Jean Claude ^a,b   Morel, Franck ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d Centre d'Innovation   (France)

^e CNRS   (France)

^f BIOAlternatives ^*  (France)

Author keywords

IL 1R; Imiquimod; MyD88; NLRP3 inflammasome; Skin inflammation

Indexed keywords

ADAPTOR PROTEIN; CASPASE; CRYOPYRIN; IMIQUIMOD; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23P19; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; AMINOQUINOLINE DERIVATIVE; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; CYTOKINE; IL1R1 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; MYD88 PROTEIN, MOUSE; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATITIS; GENE OVEREXPRESSION; IMMUNE RESPONSE; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PSORIASIS; SIGNAL TRANSDUCTION; SKIN CELL; ANIMAL; DRUG EFFECTS; DRUG ERUPTION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY; SKIN;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; CARRIER PROTEINS; CYTOKINES; DRUG ERUPTIONS; INFLAMMASOMES; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION; SKIN; TOLL-LIKE RECEPTOR 7;

EID: 84943197816     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445215     Document Type: Article

References (45)

1. Nestle, F. O., Kaplan, D. H. and Barker, J., Psoriasis. N. Engl. J. Med. 2009. 361: 496-509.
2. Nestle, F. O., Di Meglio, P., Qin, J. Z. and Nickoloff, B. J., Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009. 9: 679-691.
3. Lowes, M. A., Bowcock, A. M. and Krueger, J. G., Pathogenesis and therapy of psoriasis. Nature 2007. 445: 866-873.
4. Nickoloff, B. J., Xin, H., Nestle, F. O. and Qin, J. Z., The cytokine and chemokine network in psoriasis. Clin. Dermatol. 2007. 25: 568-573.
5. Dinarello, C. A., Immunological and inflammatory functions of the interleukin-1 family. Ann. Rev. Immunol. 2009. 27: 519-550.
6. Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schafer, M., Coyle, A. J., Renauld, J. C. et al., Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J. Clin. Invest. 2012. 122: 3965-3976.
7. Ghoreschi, K., Laurence, A., Yang, X. P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L. et al., Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010. 467: 967-971.
8. Wilson, N. J., Boniface, K., Chan, J. R., McKenzie, B. S., Blumenschein, W. M., Mattson, J. D., Basham, B. et al., Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007. 8: 950-957.
9. Jensen, L. E., Targeting the IL-1 family members in skin inflammation. Curr. Opin. Investig. Drugs 2010. 11: 1211-1220.
10. Sanmiguel, J. C., Olaru, F., Li, J., Mohr, E. and Jensen, L. E., Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAK1) dependent and independent pathways. Cell. Signal. 2009. 21: 685-694.
11. Groves, R. W., Mizutani, H., Kieffer, J. D. and Kupper, T. S., Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 [alpha] in basal epidermis. Proc. Natl Acad. Sci. USA 1995. 92: 11874-11878.
12. Mee, J. B., Johnson, C. M., Morar, N., Burslem, F. and Groves, R. W., The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am. J. Pathol. 2007. 171: 32-42.
13. Guilloteau, K., Paris, I., Pedretti, N., Boniface, K., Juchaux, F., Huguier, V., Guillet, G. et al., Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J. Immunol. 2010. 184: 5256-5270.
14. Meng, G., Zhang, F., Fuss, I., Kitani, A. and Strober, W., A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009. 30: 860-874.
15. Shepherd, J., Little, M. C. and Nicklin, M. J., Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J. Invest. Dermatol. 2004. 122: 665-669.
16. Viguier, M., Guigue, P., Pages, C., Smahi, A. and Bachelez, H., Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann. Intern. Med. 2010. 153: 66-67.
17. van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., Cornelissen, F. et al., Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 2009. 182: 5836-5845.
18. Wu, J. K., Siller, G. and Strutton, G., Psoriasis induced by topical imiquimod. Australas. J. Dermatol. 2004. 45: 47-50.
19. Baek, J. O., Byamba, D., Wu, W. H., Kim, T. G. and Lee, M. G., Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch. Dermatol. Res. 2012. 304: 699-706.
20. Cooper, K. D., Hammerberg, C., Baadsgaard, O., Elder, J. T., Chan, L. S., Taylor, R. S., Voorhees, J. J. et al., Interleukin-1 in human skin: dysregulation in psoriasis. J. Invest. Dermatol. 1990. 95: 24S-26S.
21. Debets, R., Hegmans, J., Croughs, P., Troost, R., Prins, J., Benner, R. and Prens, E., The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J. Immunol. 1997. 158: 2955-2963.
22. Mee, J. B., Cork, M. J., di Giovine, F. S., Duff, G. W. and Groves, R. W., Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine 2006. 33: 72-78.
23. Groves, R. W., Rauschmayr, T., Nakamura, K., Sarkar, S., Williams, I. R. and Kupper, T. S., Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J. Clin. Invest. 1996. 98: 336-344.
24. Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R. et al., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009. 360: 2426-2437.
25. Boniface, K., Bernard, F. X., Garcia, M., Gurney, A. L., Lecron, J. C. and Morel, F., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 2005. 174: 3695-3702.
26. Lee, E., Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004. 199: 125-130.
27. Nakajima, K., Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J. Dermatol. 2012. 39: 219-224.
28. Rabeony, H., Petit-Paris, I., Garnier, J., Barrault, C., Pedretti, N., Guilloteau, K., Jegou, J. F. et al., Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1alpha, TNFalpha and oncostatin M. PLoS One 2014. 9: e101937.
29. El Malki, K., Karbach, S. H., Huppert, J., Zayoud, M., Reisig, S., Schuler, R., Nikolaev, A. et al., An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor A signaling. J. Invest. Dermatol. 2013. 133: 441-451.
30. Van Belle, A. B., de Heusch, M., Lemaire, M. M., Hendrickx, E., Warnier, G., Dunussi-Joannopoulos, K., Fouser, L. A. et al., IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 2012. 188: 462-469.
31. Massot, B., Michel, M.-L., Diem, S., Ohnmacht, C., Latour, S., Dy, M., Eberl, G. et al., TLR-induced cytokines promote effective proinflammatory natural Th17 cell responses. J. Immunol. 2014. 192: 5635-5642.
32. Uribe-Herranz, M., Lian, L.-H., Hooper, K. M., Milora, K. A. and Jensen, L. E., IL-1R1 signaling facilitates Munro/'s microabscess formation in psoriasiform imiquimod-induced skin inflammation. J. Invest. Dermatol. 2013. 133: 1541-1549.
33. Kanneganti, T. D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J. H., Franchi, L., Whitfield, J. et al., Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006. 440: 233-236.
34. Cho, K.-A., Suh, J. W., Lee, K. H., Kang, J. L. and Woo, S.-Y., IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 2012. 24: 147-158.
35. Kayagaki, N., Warming, S., Lamkanfi, M., Walle, L. V., Louie, S., Dong, J., Newton, K. et al., Non-canonical inflammasome activation targets caspase-11. Nature 2011. 479: 117-121.
36. Walter, A., Schäfer, M., Cecconi, V., Matter, C., Urosevic-Maiwald, M., Belloni, B., Schönewolf, N. et al., Aldara activates TLR7-independent immune defence. Nat. Commun. 2013. 4: 1560-1572.
37. Coma, G., Pena, R., Blanco, J., Rosell, A., Borras, F. E., Este, J. A., Clotet, B. et al., Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clin. Exp. Immunol. 2006. 145: 535-544.
38. Schon, M. P., Schon, M. and Klotz, K. N., The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol. 2006. 126: 1338-1347.
39. Wohn, C., Ober-Blobaum, J. L., Haak, S., Pantelyushin, S., Cheong, C., Zahner, S. P., Onderwater, S. et al., Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice. Proc. Natl. Acad. Sci. USA 2013. 110: 10723-10728.
40. Flutter, B. and Nestle, F. O., TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur. J. Immunol. 2013. 43: 3138-3146.
41. Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M. et al., Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 1998. 187: 1463-1475.
42. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006. 440: 237-241.
43. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S. and Flavell, R. A., Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995. 267: 2000-2003.
44. Labow, M., Shuster, D., Zetterstrom, M., Nunes, P., Terry, R., Cullinan, E. B., Bartfai, T. et al., Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J. Immunol. 1997. 159: 2452-2461.
45. Kawai, T., Adachi, O., Ogawa, T., Takeda, K. and Akira, S., Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999. 11: 115-122.